Results 111 to 120 of about 8,221,589 (337)

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

First Publication of the Geological Society [PDF]

, 1942
Joan M. Eyles
openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Epitranscriptomic alterations induced by environmental toxins: implications for RNA modifications and disease

Genes and Environment
Epitranscriptomics, the study of chemical modifications on RNA molecules, has emerged as a vital regulatory layer in gene expression. Among the numerous RNA modifications, N6-methyladenosine (m6A), 5-methylcytosine (m5C), and pseudouridine (Ψ) are ...
Esther Ugo Alum, Regina Idu Ejemot-Nwadiaro, Mariam Basajja, Daniel Ejim Uti, Okechukwu Paul-Chima Ugwu, Patrick Maduabuchi Aja   +5 more
doaj   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Bridging the gap: telemedicine as a solution for HIV care inequities in rural and vulnerable communities

International Journal for Equity in Health
Background Despite advancements in HIV management, healthcare inequalities continue to exist, especially in rural and populations vulnerable to HIV, where factors such as distance, low income, prejudice, and a shortage of healthcare workers contribute to
Chisom Ogochukwu Ezenwaji, Esther Ugo Alum, Okechukwu Paul-Chima Ugwu   +2 more
doaj   +1 more source

Official Publications Received [PDF]

, 1931

openalex   +1 more source

Persistence of entanglement in thermal states of spin systems

, 2013
We study and compare the persistence of bipartite entanglement (BE) and multipartite entanglement (ME) in one-dimensional and two-dimensional spin XY models in an external transverse magnetic field under the effect of thermal excitations.
Gehad Sadiek, Gehad Sadiek, Ncn Publications, Purdue E-pubs, Sabre Kais, Sabre Kais   +5 more
core   +2 more sources

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

The Date of Publication [PDF]

, 1896
J. A. Allen
openalex   +1 more source